Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co-administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa-induced dyskinesias.
Bravi
D
D
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Davis
T L
TL
Mouradian
M M
MM
Chase
T N
TN
D000328:Adult; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D000078183:Oxindoles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011725:Pyridines / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology
D015259:Dopamine Agents; D007211:Indoles; D000078183:Oxindoles; D011725:Pyridines; D011954:Receptors, Dopamine; C059613:roxindole; D007980:Levodopa